May 2026
đź“Ł VC round data is live. Check it out!
Largest HealthTech Public Companies in Australia
Benchmark revenue and EBITDA valuation multiples for public comps like
Pro Medicus, Sonic Healthcare, Cochlear, Telix Pharmaceuticals and Clarity Pharmaceuticals.
 | Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe. | $91 | -54% | $10B | $9B | 61.7x | 79.7x | ||
| Sonic Healthcare is a global pathology provider. It is the largest private operator in Australia, Germany, Switzerland and the UK, the second-largest in Belgium and New Zealand, and the third largest in the US. In addition to pathology, which contributes roughly 85% of group revenue, Sonic is the second-largest player in diagnostic imaging in Australia and the largest operator of medical centers in Australia. The company typically earns about 35% of group revenue in Australia and New Zealand, 25% in the US, and 40% in Europe. | $13 | -30% | $7B | $10B | 1.5x | 8.7x | ||
| Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment. | $70 | -64% | $5B | $5B | 2.7x | 10.4x | ||
| Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer. | $10 | -49% | $3B | $4B | 4.4x | 81.7x | ||
| Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States. | $2 | +28% | $728M | $567M | — | — | ||
| Nanosonics is largely a single-product firm, and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low-temperature sonically activated hydrogen peroxide mist suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection of patients. Nanosonics’ revenue consists of capital sales of Trophon units, ongoing consumables sales, and service revenue. By December 2025, there were 38,000 Trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, over 50% in the US to single-digit penetration in Europe, Middle East, and Africa, and elsewhere in the Asia-Pacific region. | $2 | -26% | $702M | $592M | 4.2x | 26.1x | ||
| Echo IQ Ltd is an Australian medical technology company focused on improving decision-making in cardiology. Its proprietary EchoSolv platform leverages AI-driven analysis of echocardiographic data to help clinicians detect Aortic Stenosis (AS) and other conditions with greater accuracy and efficiency. The company is focused on expanding its strategic partnerships, progressing regulatory pathways, and completing successful deployments of its technology in the USA healthcare market to establish its position in AI-enabled cardiovascular care. | $1 | +529% | $660M | $652M | 9013.0x | (153.4x) | ||
| Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita’s RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months. | $1 | -13% | $560M | $552M | 6.1x | 74.0x | ||
| Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia. | $1 | -14% | $554M | $959M | 2.1x | 12.3x | ||
| Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services. | $2 | +98% | $320M | $286M | 5.4x | 16.9x | ||
| Australian Clinical Labs is Australia’s third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory. | $1 | -32% | $264M | $472M | 0.9x | 3.5x | ||
| Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialization of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry. Its product includes Striate plus; Remplir, which is a collagen wrap used in peripheral nerve repair; and OrthoACI, an implant used for the treatment of articular cartilage defects in the knee and ankle. It also has various other products in its pipeline, such as Tendon Cell Therapy and Collagen Medical Device Platform. | $1 | -34% | $156M | $125M | 20.7x | (23.8x) | ||
| EMvision Medical Devices Ltd is an Australian medical device company. The company is focused on the research and development, and commercialisation of neurodiagnostic technology for stroke diagnosis and monitoring, as well as other medical imaging needs. Its focus is portable, cost-effective, and non-invasive brain scanners, including a bedside device (emu) and an ultra-lightweight pre-hospital device (First Responder). Its first indication targets acute stroke care, with a second planned indication in traumatic brain injury. | $1 | -1% | $111M | $101M | — | — | ||
| Alcidion Group Ltd is a provider of intelligent informatics software. It offers a fully integrated digital patient care platform that includes a clinical decision support (CDS) system, Electronic Patient Record (EPR), and Patient Administration System (PAS). Alcidion is engaged in the development and licensing of its own healthcare software products (Miya Precision and its associated modules, including Miya Observations, Flow, Task Management and PAS), the reselling of healthcare software products from its strategic partners, and the delivery of product implementation, product support and maintenance, systems integration and data analysis services to healthcare customers in the United Kingdom, Australia, and New Zealand. The company generates maximum revenue from the United Kingdom. | $0 | +28% | $105M | $96M | 3.6x | 26.9x | ||
| Optiscan Imaging Ltd is engaged in the development, manufacture, and commercialization of endomicroscopic digital imaging technology solutions for medical, translational, and pre-clinical applications. Its technology offers real-time, 3D, in vivo imaging at the single-cell level, in a non-destructive manner that enables clinicians to make immediate informed decisions. Its products include InVivage, ViewnVivo, and Customisation. Its geographical segments include Australia, Germany, Norway, China, and the United States. | $0 | -26% | $82M | $70M | 103.6x | (16.9x) | ||
| BlinkLab Ltd is a company that has the license to commercialize the Licensed IP and has developed a smartphone-based application with an e-platform that serves as a medical device to perform neurometric tests to aid in the diagnosis of ASD, ADHD, schizophrenia, and other neurodevelopmental conditions. The results from the BlinkLab Tests are recorded by smartphone and uploaded to BlinkLab’s confidential and secure online platform where the data is analyzed. | $1 | -- | $79M | $75M | — | — | ||
| Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment. | $1 | -39% | $66M | $66M | 2.9x | (5.8x) | ||
| PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business. | $0 | +38% | $52M | $50M | 9.6x | 50.5x | ||
| Singular Health Group Ltd provides medical software solutions. The company's business segment is the provision of Volume Rendering Platform (VRP) software, providing 3D printing services and 3D machine sales. It operates in one segment, which is the provision and development of medical technology within Australia. | $0 | -- | $45M | $37M | 257.7x | (8.5x) | ||
| AnteoTech Ltd is a biotechnology company engaged in the development of specialty products and services and end-user diagnostic products focused on the Battery and Life Science diagnostics markets. Its key areas are the Energy and Life Science Division. The company is developing four products named AnteoX, Ultranode, AnteoBind NXT, and AnteoBind these products are used in the energy, diagnostic, and medical device markets. The company currently has a single segment which is the development of the AnteoTech IP. | $0 | +126% | $38M | $38M | 55.4x | (10.4x) | ||
| Beamtree Holdings Ltd is an Artificial intelligence (AI) health technology company. It offers software solutions like Picq, RippleDown, Risq, Ainsoff, Q Coding platform, and others across four product segments that combine into a modular software suite to assist healthcare services in transforming the quality of their data, analyzing key performance insights, and improving actionable decision support. The company's key operating product segments are: Knowledge Networks, which generate maximum revenue, Diagnostics, Clinical Decision Support, and Coding and Data Quality Assurance. Geographically, it operates in Australia, its key revenue-generating market, Europe, and the Rest of the world. | $0 | -68% | $19M | $19M | 0.9x | (82.0x) | ||
| CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company’s CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform. | $0 | -47% | $17M | $27M | 3.1x | (3.7x) | ||
| Proteomics International Laboratories Ltd is a biological research and drug discovery company. It is a pioneering medical technology company operating at the forefront of predictive diagnostics and precision medicine. The Company specialises in proteomics-the industrial-scale study of the structure and function of proteins. Its pipeline includes Promarker, Pipeline PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx. | $0 | -63% | $17M | $12M | 5.2x | (2.5x) | ||
| Conneqt Health Ltd is a health technology company, developing solutions for health disorders. The company designs medical devices for use in cardiovascular health management. The company is mainly engaged in manufacturing biomarkers that helps to detect associated risks, optimize heart health, and empower good cardiovascular decisions. | $0 | -- | $16M | $17M | 6.8x | (1.4x) | ||
| ImExHS Ltd is engaged in the development and sale of its Hiruko software platform. The software consists of Radiology, Cardiology, Pathology information systems, and Picture Archiving and Communications Systems. The segments of the company are Software and Radiology Services. The company derives maximum revenue from Radiology segment. | $0 | -- | $14M | $12M | 0.6x | 10.3x | ||
| Median | $1 | -26% | $111M | $101M | 4.8x | 6.1x |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.